sasanlimab Report issue

Biologics mAb Experimental
AACT

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

pf-06801591

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (26)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (26)


 

Bile Duct Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Cholangiocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 1)

Endometrial Neoplasms (Phase 1)

Esophageal Neoplasms (Phase 1)

Head and Neck Neoplasms (Phase 1)

Intestinal Neoplasms (Phase 1)

Liver Neoplasms (Phase 1)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 2)

Melanoma (Phase 1)

Mesothelioma (Phase 2)

Mesothelioma, Malignant (Phase 1/Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 1/Phase 2)

Pancreatic Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Sarcoma (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Stomach Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue